Peptide side effects by class: what to expect and what is a red flag

Every subcutaneous peptide can cause a small red, itchy or slightly raised spot where the needle went in. It appears within an hour, fades within a day or two, and is a reaction to the needle and the solution rather than to the peptide's mechanism. Bruising happens when the needle nicks a capillary. Small firm lumps form when the same spot is used repeatedly, which is why every compound page says rotate sites. None of these mean anything is wrong with the product.

Some compounds sting more than others. GHK-Cu is the worst offender, with stinging and bruising described as very common above 2 mg per mL. Tesamorelin and sermorelin list site reactions as their most frequent complaint. Technique helps: letting the syringe warm in your hand, injecting slowly, and keeping a finger width between sites. Where to inject peptides covers the rest. A site that gets hotter, harder and more painful over 24 to 48 hours instead of fading is infection until proven otherwise.

The GLP-1 class slows stomach emptying and signals fullness, and the side effects follow directly. Nausea is the most common, worst in the first few days after each dose increase and usually settling within the step. Constipation or diarrhea, burping, reflux and early fullness are routine. Fatigue in the first weeks of each step comes from eating less. Hair shedding a few months into rapid weight loss is a known pattern with any fast loss and tends to reverse. The compound pages for semaglutide and tirzepatide both describe escalating too fast as the number one mistake.

The label titration exists to manage exactly this. Semaglutide starts at 0.25 mg weekly for 4 weeks before stepping up; tirzepatide starts at 2.5 mg weekly for 4 weeks and increases by 2.5 mg no sooner than every 4 weeks. Skipping the starting dose or jumping a step produces most of the vomiting stories. Retatrutide adds a heart rate increase as the extra signal seen in its trials.

The serious effects are rare and specific. Pancreatitis presents as severe, persistent abdominal pain, sometimes radiating to the back; the UK MHRA issued a safety alert about it in January 2026. Gallbladder problems show as pain under the right ribs, fever or yellowing skin. The class carries a rodent thyroid tumor warning, so a neck lump, hoarseness or trouble swallowing is a stop.

Anything that raises growth hormone raises fluid retention. Puffy hands and feet, joint aches and stiffness, and tingling or numb fingers from pressure on the carpal tunnel are the signature effects, and they scale with dose. HGH lists them as very common above 2 IU daily. CJC-1295 with DAC is the tricky one because its 6 to 8 day half-life means side effects cannot be stopped by skipping a dose; they linger for weeks.

The GHRPs add their own layer. Ipamorelin was designed to avoid the hunger, cortisol and prolactin spikes of older GHRPs, but headache, flushing and lightheadedness right after a dose are common early on and usually fade, and a mild appetite increase shows up in some people. Drowsiness after daytime doses is why bedtime dosing is standard. Sermorelin and tesamorelin, the GHRH analogs, mostly cause site reactions, flushing and headache, with the fluid effects appearing when stacked or at the top of the range.

The effects that matter are metabolic. Growth hormone pushes blood glucose up in the hours after a pulse and reduces insulin sensitivity over time, so fasting glucose and HbA1c drifting upward is a stop signal across the whole class. IGF-1 above the reference range for your age on repeat testing is another. Persistent carpal tunnel symptoms that do not resolve at a lower dose, and any new lump or cancer diagnosis, round out the list.

PT-141 and Melanotan-2 both act on melanocortin receptors and share a side effect profile. Nausea is the headline: around 40 percent of PT-141 trial participants reported it, and for Melanotan-2 it is described as nearly universal for the first several doses. Flushing and facial redness, headache, and a few hours of fatigue, yawning and stretching after a dose are common. Both raise blood pressure, PT-141 by about 6 mmHg systolic for up to 12 hours, which is why uncontrolled hypertension and cardiovascular disease are contraindications and stimulants are best avoided alongside.

The effect unique to this class is pigmentation. Melanotan-2 darkens existing moles and freckles and can produce new ones, and melanoma has been reported in users. PT-141, at the doses used for libido, can also darken skin, gums and moles with repeated use, more so in people with darker skin. A mole that changes size, shape, color or border, or any new dark lesion, is a stop and a dermatology visit.

PT-141 has a labeled frequency limit: no more than one dose in 24 hours and no more than 8 per month. Exceeding it is itself listed as a reason to stop.

Semax and Selank are mostly used intranasally, so their side effects are mostly nasal: irritation, dryness and occasional nosebleeds with frequent spraying. Semax can cause restlessness or irritability at higher doses and trouble sleeping when dosed late in the day, and a minority of long term users report hair thinning, which has not been studied. Selank tends the other way, with fatigue or emotional flatness at higher doses in some people and no noticeable effect at all in a fair share of users.

Stop signals for both are modest: persistent nosebleeds or nasal pain, insomnia that does not resolve after moving doses earlier, and anxiety or irritability getting worse rather than better.

Day to day, BPC-157 and TB-500 are among the mildest compounds on the site. BPC-157 users report site redness, nausea (more with oral capsules), occasional headache or brief dizziness, and a warm flush or transient fatigue after a dose. TB-500 adds fatigue, lethargy or a head rush for a few hours after larger doses and occasional lightheadedness on standing.

The concern is not what you feel. Both compounds promote blood vessel growth and cell migration, which is the point for a torn tendon and a theoretical problem for an undetected tumor. Thymosin beta-4 is expressed in many tumor types. No human data exists either way, so the compound pages treat a new lump, mass or skin lesion anywhere as a hard stop, along with any cancer diagnosis or the start of cancer treatment. Pain or swelling at the injury getting worse rather than better after two weeks is the other stop, since the compound is not doing its job and something else may be going on.

Topically, GHK-Cu and AHK-Cu can cause irritation, redness or itching, more likely with high copper content, with microneedling, or in people sensitive to copper, where it can progress to contact dermatitis. A temporary increase in shedding in the first weeks of a scalp product is reported, as it is with most hair treatments. A blue-green tint on light hair or pillowcases is cosmetic rather than harmful.

Injected GHK-Cu is a different experience. Stinging, redness and bruising are very common, with a metallic taste or brief nausea in some users. The stop signals are a site that becomes hard, hot or increasingly painful rather than settling, a persistent rash or hives, and anything pointing to copper overload: unusual fatigue, abdominal pain or jaundice. People with Wilson disease or any copper metabolism disorder should not use it by any route.

Most of what is above is nuisance level and manageable with a lower dose, slower escalation or better technique. The list below is the other category: symptoms that mean stop the compound now and get checked, drawn from the stop rules across the compound pages.